An aggravated trajectory of depression and anxiety co-morbid with hepatitis C: : A 21 to 62 month follow-up study in 61 South Australian outpatients by Stewart, Benjamin et al.
Send Orders for Reprints to reprints@benthamscience.ae 
174 Clinical Practice & Epidemiology in Mental Health, 2015, 11, 174-179  
 
 1745-0179/15 2015 Bentham Open 
Open Access 
An Aggravated Trajectory of Depression and Anxiety Co-morbid with 
Hepatitis C: A Within-groups Study of 61 Australian Outpatients 
Benjamin J.R. Stewart
1,*
, Deborah Turnbull
1
, Antonina A. Mikocka-Walus
2
, Hugh Harley
4
  
and Jane M. Andrews
3,4
  
1
School of Psychology, University of Adelaide, Australia; 
2
Department of Health Sciences, University of York, United 
Kingdom; 
3
Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Australia; 
4
Discipline of Medi-
cine, University of Adelaide, Australia 
Abstract: Background: This study aimed to explore the course of depression and anxiety in chronic hepatitis C patients. 
Methods:  Data were combined from two studies: (1) Hospital Anxiety and Depression Scale (HADS) scores in 395 con-
secutive Australian outpatients from 2006 to 2010 formed the baseline measurement; and (2) Depression Anxiety Stress 
Scales (DASS) scores in a survey of a sub-sample of these patients in 2011 formed the follow-up measurement. After 
converting DASS to HADS scores, changes in symptom scores and rates of case-ness (?8), and predictors of follow-up 
symptoms were assessed. Results:  Follow-up data were available for 61 patients (70.5% male) whose age ranged from 
24.5 to 74.6 years (M=45.6). The time to follow-up ranged from 20.7 to 61.9 months (M=43.8). Baseline rates of depres-
sion (32.8%) and anxiety (44.3%) increased to 62.3% and 67.2%, respectively. These findings were confirmed, independ-
ent of the conversion, by comparing baseline HADS and follow-up DASS scores with British community norms. Baseline 
anxiety and younger age predicted depression, while baseline anxiety, high school non-completion, and single relationship 
status predicted anxiety. Conclusion:  This study demonstrated a worsening trajectory of depression and anxiety. Further 
controlled and prospective research in a larger sample is required to confirm these findings. 
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INTRODUCTION 
Psychiatric co-morbidity is prevalent in chronic hepatitis 
C [CHC; 1] and results in diminished quality of life [2], in-
creased fatigue [3, 4] and pain [5], and impaired anti-viral 
treatment outcomes [6]. It appears that CHC itself may be 
particularly associated with poorer mental health outcomes, 
with research showing that the rate of major depression was 
higher in CHC patients compared with controls or chronic 
hepatitis B patients [7]. Psychosocial stressors are a contrib-
uting factor to this morbidity, and include the adverse effect 
of diagnosis, anti-viral treatment, stigma, and fears regarding 
disease progression or viral transmission [8]. Research has 
demonstrated poorer quality of life in people aware of their 
CHC infection compared with those unaware [9, 10]. Thus, 
the ability of patients to adjust to, and cope with, psychoso-
cial stressors accompanying and following the diagnosis of 
CHC may be critical in determining the longitudinal course 
of psychiatric disorders. However, little is known about the 
course of psychiatric co-morbidity in this cohort. This study 
aimed to assess the course of depression and anxiety symp-
toms in a cohort of South Australian CHC outpatients of the 
Royal Adelaide Hospital (RAH) liver clinic. 
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MATERIALS AND METHODOLOGY 
Design and Participants 
This within-subjects study combined and compared data 
collected on a sub-set of CHC outpatients from two previous 
studies. In the first [11], Hospital Anxiety and Depression 
Scale [HADS; 12] scores, collected as part of standard clini-
cal care at appointments at the RAH liver clinic from 2006, 
were analysed to explore the prevalence and predictors of 
depression and anxiety in 395 consecutive CHC outpatients 
from 2006-2010. In the second [13], CHC outpatients from 
this clinic completed a postal survey in late 2011 and early 
2012 exploring psychological treatment acceptability, in-
cluding a measurement with the Depression Anxiety Stress 
Scales [14]. Data available for participants of both studies 
(n=61) were collated to assess the level of depression and 
anxiety at the two  points of assessment. 
Procedure 
A recent study facilitated a method of converting scores 
between the HADS and DASS. Covic and colleagues [15] 
measured depression and anxiety in British and Australian 
Rheumatoid Arthritis (RA) patients using the HADS and the 
DASS. Through use of Rasch Analysis, they were able to 
calibrate the two scales by mapping scores on to a common 
underlying metric of psychopathology. The present study 
applied this metric to convert DASS scores at follow-up in 
2011 to HADS scores. A cut-off score ? 8 on the HADS was 
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used to determine depression or anxiety, in accordance with 
recommendations [16, 17]. The ethics committees of the 
RAH and University of Adelaide provided approval for the 
two studies comprising it the data for this paper. This re-
search was conducted in accordance with the Declaration of 
Helsinki. 
Analysis 
Differences between HADS scores at baseline (T1) and 
converted HADS scores at follow-up (T2) were compared 
using repeated samples t-tests. Rates of case-ness at T1 and 
T2 were compared using McNemar’s test. Levels of depres-
sion and anxiety were compared against British norms for T1 
HADS scores [18] and T2 DASS scores [19], and the dis-
crepancy between effect sizes analysed, in order to provide 
an assessment of change independent of DASS conversion. 
Univariate associations with T2 HADS scores were con-
ducted using Pearson’s correlation for continuous predictors 
and independent samples t-tests for categorical predictors. 
Multivariate associations were tested using linear regression 
models with hierarchical entry of predictors with a univariate 
association of p<0.05, with baseline depression and anxiety 
scores entered at Step 1, and all other predictors at Step 2. 
RESULTS 
Socio-demographic and medical data is presented in  
Table 1. Of the 61 participants for whom T1 and T2 data was 
available, 43 (70.5%) were male. Their age ranged from 
24.49 to 74.61 years (M=45.61, SD=10.08) and the time 
between T1 and T2 assessments ranged from 20.64 to 61.92 
months (M=43.80, SD=12.24). 
As shown in Table 2, depression and anxiety rates in-
creased by T2. The odds of developing new depressive case-
ness by T2 was 10 times higher than the odds of T1 cases 
going into remission from depression (p<0.001, 95% 
CI:2.34-42.78). Similarly, the odds of developing anxiety 
case-ness by T2 was 4.5 times higher than the odds of remis-
sion from anxiety by T2 (p=0.004, 95% CI:1.52-13.30). Fi-
nally, the odds of developing co-morbidity by T2 was 4 
times higher than the odds of remission from co-morbidity 
by T2 (p=0.004, 95% CI:1.50-10.66). 
As shown in Fig. (1), the sample as a whole experienced 
a significant increase in both depression (t(60)=6.41, 
p<0.001, d=0.82) and anxiety (t(60)=4.08, p<0.001, d=0.52) 
from T1-T2. When analysed based on case-ness at T1, de-
pression scores increased significantly in patients without 
baseline case-ness (t(31)=6.28, p<0.001, d=1.15) and with 
one baseline disorder (t(10)=2.87, p=0.017, d=0.88) but not 
in those with T1 co-morbidity (t(17)=1.64, p=0.120, d=0.39). 
Anxiety scores increased significantly in those without base-
line case-ness (t(31)=5.24, p<0.001, d=1.01) and remained 
stable in those with one baseline disorder (t(10)=0.75, 
p=0.473, d=0.23) or T1 co-morbidity (t(17)=0.53, p=0.605, 
d=0.13). 
Table 1.  Socio-demographic and medical characteristics of patients. 
Categorical variables n? %?
Male? 43? 70.5?
Gender?
Female? 18? 29.5?
Non-high school completer? 28? 45.9?
Education?
High school completer? 33? 54.1?
Not partnered? 42? 73.7?
Relationship status?
Partnered? 19? 26.3?
Born in Australia? 44? 72.1?
Nationality?
Born overseas? 17? 27.9?
No? 20? 32.8?
Previous IDU?
Yes? 41? 67.2?
No? 30? 49.2?
Anti-viral treatment from T1 to T2?
Yes? 31? 50.8?
No? 43? 70.5?
SVR from T1 to T2?
Yes? 18? 29.5?
Continuous variables? Range? M? SD?
Age (years)? 24.49 – 74.61? 45.61? 10.08?
SEIFA? 807 – 1098? 952.48? 77.52?
Time since diagnosis (years)? 1 – 40? 12.51? 8.07?
T1 to T2 interval (months)? 20.70 – 61.93? 43.78? 12.21?
IDU=Injecting drug use, SEIFA=Socio-Economic Index For Areas Index of Advantage/Disadvantage, based on post-code areas. 
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Table 2.  Depression and anxiety case-ness rates at T1 and T2. 
Number of cases † (%)?
Case-ness type 
Baseline? Follow-up?
Depression‡? 20 (32.8)? 38 (62.3)?
Depression alone? 2 (3.3)? 5 (8.2)?
Anxiety‡? 27 (44.3)? 41 (67.2)?
Anxiety alone? 9 (14.8)? 8 (13.1)?
Any disorder? 29 (47.5)? 46 (75.4)?
One disorder? 11 (18.0)? 13 (21.3)?
Co-morbid disorders? 18 (29.5)? 33 (54.1)?
† Cases are based on HADS subscale scores ? 8 ‡ Cases with ‘Depression’ or ‘Anxiety’ may also exhibit case-ness of the other disorder type, as compared with ‘Depression alone’ or 
‘Anxiety alone’ wherein these cases only exhibit case-ness of that disorder type. 
 
 
Fig. (1).  
 
As shown in Fig. (2), at T1 the present sample was sig-
nificantly disadvantaged and was compared to British com-
munity HADS norms with respect to both depression 
(t(1851)=4.03, p<0.001, Cohen’s d=0.46) and anxiety 
(t(1851)=2.43, p=0.015, Cohen’s d=0.29). When DASS 
scores were compared to British norms at T2, this discrep-
ancy had widened markedly for both depression 
(t(1853)=11.83, p<0.001, Cohen’s d=1.15) and anxiety 
(t(1853)=12.44, p<0.001, Cohen’s d=1.16). 
Univariate predictors of depression and anxiety at T2 
were then assessed, including age at T1, gender, nationality, 
education, the Socio-Economic Index For Areas (SEIFA) 
relative socio-economic advantage and disadvantage index 
based on post-code areas at T1 [20], relationship status at T1, 
previous injecting drug use (IDU), years since diagnosis at 
T2, the time between T1 and T2 assessments, anti-viral treat-
ment between T1 and T2, achieving an SVR between T1 and 
T2, and T1 anxiety and depression. Depression and anxiety 
at T1 were significantly and positively correlated with both 
depression and anxiety scores at T2, while age at T1 was 
negatively correlated with depression scores at T2. Those 
Those who had completed high school and those who were 
in a relationship at T1 had significantly lower depression and 
anxiety scores at T2. 
Significant univariate predictors were then entered into 
the multivariate analysis, as shown in Table 3. On step 1, T1 
depression and anxiety scores were entered. Only anxiety 
was  at T1 independently predicted both depression and 
anxiety scores at T2. At step 2, education and relationship 
status were entered into both models and age was added to 
the depression model. Age remained significant and ex-
plained an additional 11% of the variance in depression 
scores at T2, while education and relationship status re-
mained significant and explained an additional 17% of the 
variance in anxiety at T2. 
DISCUSSION 
This study demonstrated a poor trajectory of depression 
and anxiety in which four groups could be identified: (1) 
those who were non-cases at both baseline and follow-up 
(23.0%); (2) those who were non-cases at baseline, but 
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Fig. (2). 
 
Table 3.  Multivariate analyses of T2 depression and anxiety. 
T2 Depression? T2 Anxiety?
Variable 
b? SE b? ?? b? SE b? ??
Step 1? Constant? 5.64? 0.87? ? 6.61? 1.10? ?
T1 Depression? 0.15? 0.15? .16? 0.03? 0.19? .03?
?
T1 Anxiety? 0.32? 0.13? .38*? 0.41? 0.16? .40*?
Step 2? Constant? 10.10? 3.42? ? 6.52? 3.07? ?
T1 Depression? 0.11? 0.14? .11? -0.10? 0.17? -.08?
?
T1 Anxiety? 0.29? 0.12? .35*? 0.42? 0.15? .42**?
? Age? -0.09? 0.04? -.23*? -? -? -?
High school completion? -1.59? 0.90? -.20? -2.90? 1.10? -.30*?
?
Relationship status? 1.56? 1.01? .18? 3.03? 1.23? .28*?
For T2 depression, Step 1 Adjusted R2=0.22, Step 2 ?R2=0.11 (ps<0.05). 
For T2 anxiety, Step 1 Adjusted R2=0.15, Step 3 ?R2=0.17 (ps<0.01). 
* p<0.05, ** p<0.01 
 
whose symptoms increased to case-ness thresholds by fol-
low-up (29.5%); (3) those who were cases at baseline and 
follow-up (45.9%); and (4) the sole individual who was a 
case at baseline and recovered by follow-up (1.6%). Two 
studies have also reported worsening in symptoms over time 
in Crohn’s disease [21] and cardiovascular patients [22]. 
However, these findings contradict the stability reported over 
one year in two smaller studies with CHC [23, 24]. Moreo-
ver, research in other populations have reported stability over 
time, including in the general population [25] and those with 
HIV [26, 27], irritable bowel syndrome and inflammatory 
bowel disease [24, 28], cardiovascular disease [29, 30], and 
RA [31, 32]. 
It is possible that the aggravated course observed here 
can be explained by the differential nature of CHC and the 
psychosocial stressors it poses and/or the nature of the popu-
lations that typically acquires CHC – comprising mostly cur-
rent or former IDUs (67% in this cohort). Also, previous 
research has reported a worse prognosis for those with co-
morbid depression and anxiety [33, 34], which is common in 
CHC patients [1] and, particularly, in the cohort from which 
this sample was drawn [11]. 
However, this does not account for the aggravation in 
those without morbidity at baseline - the group in which the 
main symptom increase occurred. The correlation between 
depression and anxiety scores at baseline provides insight 
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into the general level of co-morbid symptomatology in the 
sample regardless of case-ness. In the British community, the 
correlation between HADS anxiety and depression scores is 
moderate (r=0.53, p<0.001). In the cohort from which the 
present sample was drawn [11], the correlation is signifi-
cantly higher (r=0.66, Z=3.63, p<0.001), indicating a higher 
degree of co-morbid symptoms in this patient group. 
Interestingly, time since diagnosis was not related to de-
pression or anxiety at follow-up. There was also no associa-
tion between the change in psychopathology and the variable 
time difference between the baseline and follow-up assess-
ments across patients. This suggests that the aggravation in 
symptoms being observed may not be stemming from a fail-
ure and  to adjust with the diagnosis of CHC per se or from 
the mere passage of time. It is possible that the progression 
observed reflects a difficulty in adjusting to new psychoso-
cial stressors, such as disease progression and treatment con-
siderations. These stressors do not occur at predictable time 
points following diagnosis, as CHC can progress quite 
slowly and patients may present for specialist treatment at 
different times following diagnosis. 
In the multivariate analysis, baseline anxiety, but not de-
pression, remained an independent predictor of both in-
creased depression and anxiety at follow-up. This is sup-
ported by longitudinal community-based studies which have 
found that anxiety leads to depression more often than the 
reverse [33, 35]. After accounting for baseline depression 
and anxiety, age remained a significant predictor of de-
creased depression at follow-up, while education and rela-
tionship status remained independent predictors of decreased 
anxiety - consistent with other research [25, 36].  
LIMITATIONS 
This study has a number of limitations. There were no 
control comparison subjects and the length of follow-up var-
ied, due to this studies post-hoc use of routinely collected 
clinical data as the baseline measurement. While the present 
cohort was compared with normative data.The sample size 
was too small to match the age and gender which can influ-
ence the expression of mood and anxiety symptoms. Data 
was not available for whether patients were diagnosed with 
specific disorders. Symptoms of depression and anxiety can 
be present across varying mood and anxiety disorders as well 
as in other psychiatric illnesses including personality and 
psychotic disorders. It was also not possible to analyse pre-
vious or current psychiatric treatment. The sample was small 
and the participants of the second study who provided fol-
low-up data were self-selected [13], introducing the possibil-
ity of sample biases. However, excluding a slightly lower 
response rate in previous recipients of anti-viral treatment 
(16% vs. 25%), there were no differences between survey 
responders and non-responders [13]. Critically, there were 
no differences in HADS scores. Thus, both non-responders 
and responders to the survey experienced comparable mental 
health at baseline. However, it is possible those who experi-
enced a worse course of depression and anxiety after that 
baseline measurement were more inclined to respond at fol-
low-up because the issue was more personally salient. The 
multivariate analysis should especially be regarded with cau-
tion due to the small sample size and relatively large number 
of predictor variables are used. 
 The procedure of converting DASS scores at follow-up 
with HADS scores to compare symptoms rely  on the as-
sumption that the calibration of DASS and HADS scores by 
Covic and colleagues [15] is robust and equivalent between 
RA and CHC patients. To verify the findings independent of 
this conversion and its assumptions, baseline HADS and 
follow-up DASS scores were compared separately to British 
norms for the HADS [18] and DASS [19], respectively. At 
baseline, the present sample had significantly worse HADS 
scores than British norms. However, by follow-up this dis-
advantage, in comparison to British norms for the DASS, 
had inflated by a factor of 2.5 for depression and 4 for anxi-
ety.  
Finally, subjects who achieved a SVR between baseline 
and follow-up assessments were included, as many receive 
ongoing care to assess for viral relapse and manage existing 
liver damage. If the SVR rates of the sample that provided 
follow-up data were lower than normal, this could explain 
their poorer mental health. However, of the 31 patients who 
received anti-viral treatment, 58% achieved a SVR, consis-
tent with rates in those treated with interferon and ribavirin 
[37]. Moreover, SVR was not associated with follow-up de-
pression or anxiety in this study.  
CONCLUSION 
This study found a high rate of co-morbid depression and 
anxiety which increased markedly over a period of up to five 
years in a small sample of Australian CHC outpatients. Fu-
ture research would benefit from a controlled, prospective 
analysis in a larger sample, involving multiple assessments 
of symptoms and a focus on potential intervening variables 
such as psychiatric treatment, social support, and changes in 
CHC to related psychosocial stressors. 
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